OUR PORTFOLIO

Oxford Nanopore
Auris Health
BJ Bioscience
GI Windows Surgical
Exscientia
Apeiron
Boundless Bio

Latest information

Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by

Boundless Bio announced the closing of a $100 million Series C financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from additional new investors, Sectoral Asset Management and Piper Heartland Healthcare Capital. Boundless Bio will use the financing to advance BBI-355, the first ecDNA-directed therapy (ecDTx), through meaningful clinical readouts from its ongoing Phase 1/2 clinical trial in patients with oncogene-amplified cancers.

Read more ›